skynesher
Akero Therapeutics (NASDAQ:AKRO) has entered into a definitive agreement to be acquired by Novo Nordisk (NVO) for up to $5.2 billion in cash, it said on Thursday, boosting shares ahead of the market open.
Under the terms of the agreement, Akero (
